Impacts of leuprolide acetate on quality of life in patients with prostate cancer: A prospective multicenter study

Dalsan You, In Gab Jeong, Sae Woong Kim, Byung Ha Chung, Jin Seon Cho, Hyun Moo Lee, Sung Cheol Yun, Choung Soo Kim

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objective. To investigate the impacts of leuprolide acetate on the quality of life (QoL) of patients with prostate cancer. Material and methods. A total of 104 patients was enrolled in this prospective multicenter study. All patients received subcutaneous injections of 3.75 mg leuprolide acetate at 4 week intervals for a total of 12 weeks. QoL was assessed before treatment and at 12 weeks using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) and an accompanying prostate cancer-specific module (QLQ-PR25). Results. Eighty-nine of 104 patients (85.6%) completed the 12 week study. Eighty-six of 89 patients (96.6%) achieved and maintained medical castration. The results of the EORTC QLQ-C30 indicated that patients experienced an improvement in global health status/QoL (p < 0.001), despite a deterioration in physical and role functioning (p=0.012 and p=0.007, respectively). The symptom scales indicated a statistically significant improvement in appetite (p=0.003). The results of the QLQ-PR25 revealed that patients experienced an increase in hot flushes (p < 0.001) and erection problems and uncomfortable sexual intimacy among the sexual functioning items (p=0.030 and p=0.023, respectively), but day-time urinary frequency was improved (p=0.004). Conclusion. The results of this prospective study indicate that leuprolide acetate treatment was accompanied by improvements in global health status/QoL, despite a deterioration in physical, role and sexual function.

Original languageEnglish
Pages (from-to)399-405
Number of pages7
JournalScandinavian Journal of Urology and Nephrology
Volume44
Issue number6
DOIs
Publication statusPublished - 2010 Dec 1

Fingerprint

Leuprolide
Multicenter Studies
Prostatic Neoplasms
Quality of Life
Prospective Studies
Health Status
Organizations
Castration
Appetite
Subcutaneous Injections
Therapeutics
Research
Neoplasms

All Science Journal Classification (ASJC) codes

  • Nephrology
  • Urology

Cite this

You, Dalsan ; Jeong, In Gab ; Kim, Sae Woong ; Chung, Byung Ha ; Cho, Jin Seon ; Lee, Hyun Moo ; Yun, Sung Cheol ; Kim, Choung Soo. / Impacts of leuprolide acetate on quality of life in patients with prostate cancer : A prospective multicenter study. In: Scandinavian Journal of Urology and Nephrology. 2010 ; Vol. 44, No. 6. pp. 399-405.
@article{d014963fc44d4079bf001cc328c374e0,
title = "Impacts of leuprolide acetate on quality of life in patients with prostate cancer: A prospective multicenter study",
abstract = "Objective. To investigate the impacts of leuprolide acetate on the quality of life (QoL) of patients with prostate cancer. Material and methods. A total of 104 patients was enrolled in this prospective multicenter study. All patients received subcutaneous injections of 3.75 mg leuprolide acetate at 4 week intervals for a total of 12 weeks. QoL was assessed before treatment and at 12 weeks using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) and an accompanying prostate cancer-specific module (QLQ-PR25). Results. Eighty-nine of 104 patients (85.6{\%}) completed the 12 week study. Eighty-six of 89 patients (96.6{\%}) achieved and maintained medical castration. The results of the EORTC QLQ-C30 indicated that patients experienced an improvement in global health status/QoL (p < 0.001), despite a deterioration in physical and role functioning (p=0.012 and p=0.007, respectively). The symptom scales indicated a statistically significant improvement in appetite (p=0.003). The results of the QLQ-PR25 revealed that patients experienced an increase in hot flushes (p < 0.001) and erection problems and uncomfortable sexual intimacy among the sexual functioning items (p=0.030 and p=0.023, respectively), but day-time urinary frequency was improved (p=0.004). Conclusion. The results of this prospective study indicate that leuprolide acetate treatment was accompanied by improvements in global health status/QoL, despite a deterioration in physical, role and sexual function.",
author = "Dalsan You and Jeong, {In Gab} and Kim, {Sae Woong} and Chung, {Byung Ha} and Cho, {Jin Seon} and Lee, {Hyun Moo} and Yun, {Sung Cheol} and Kim, {Choung Soo}",
year = "2010",
month = "12",
day = "1",
doi = "10.3109/00365599.2010.508048",
language = "English",
volume = "44",
pages = "399--405",
journal = "Scandinavian Journal of Urology",
issn = "2168-1805",
publisher = "Informa Healthcare",
number = "6",

}

Impacts of leuprolide acetate on quality of life in patients with prostate cancer : A prospective multicenter study. / You, Dalsan; Jeong, In Gab; Kim, Sae Woong; Chung, Byung Ha; Cho, Jin Seon; Lee, Hyun Moo; Yun, Sung Cheol; Kim, Choung Soo.

In: Scandinavian Journal of Urology and Nephrology, Vol. 44, No. 6, 01.12.2010, p. 399-405.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Impacts of leuprolide acetate on quality of life in patients with prostate cancer

T2 - A prospective multicenter study

AU - You, Dalsan

AU - Jeong, In Gab

AU - Kim, Sae Woong

AU - Chung, Byung Ha

AU - Cho, Jin Seon

AU - Lee, Hyun Moo

AU - Yun, Sung Cheol

AU - Kim, Choung Soo

PY - 2010/12/1

Y1 - 2010/12/1

N2 - Objective. To investigate the impacts of leuprolide acetate on the quality of life (QoL) of patients with prostate cancer. Material and methods. A total of 104 patients was enrolled in this prospective multicenter study. All patients received subcutaneous injections of 3.75 mg leuprolide acetate at 4 week intervals for a total of 12 weeks. QoL was assessed before treatment and at 12 weeks using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) and an accompanying prostate cancer-specific module (QLQ-PR25). Results. Eighty-nine of 104 patients (85.6%) completed the 12 week study. Eighty-six of 89 patients (96.6%) achieved and maintained medical castration. The results of the EORTC QLQ-C30 indicated that patients experienced an improvement in global health status/QoL (p < 0.001), despite a deterioration in physical and role functioning (p=0.012 and p=0.007, respectively). The symptom scales indicated a statistically significant improvement in appetite (p=0.003). The results of the QLQ-PR25 revealed that patients experienced an increase in hot flushes (p < 0.001) and erection problems and uncomfortable sexual intimacy among the sexual functioning items (p=0.030 and p=0.023, respectively), but day-time urinary frequency was improved (p=0.004). Conclusion. The results of this prospective study indicate that leuprolide acetate treatment was accompanied by improvements in global health status/QoL, despite a deterioration in physical, role and sexual function.

AB - Objective. To investigate the impacts of leuprolide acetate on the quality of life (QoL) of patients with prostate cancer. Material and methods. A total of 104 patients was enrolled in this prospective multicenter study. All patients received subcutaneous injections of 3.75 mg leuprolide acetate at 4 week intervals for a total of 12 weeks. QoL was assessed before treatment and at 12 weeks using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) and an accompanying prostate cancer-specific module (QLQ-PR25). Results. Eighty-nine of 104 patients (85.6%) completed the 12 week study. Eighty-six of 89 patients (96.6%) achieved and maintained medical castration. The results of the EORTC QLQ-C30 indicated that patients experienced an improvement in global health status/QoL (p < 0.001), despite a deterioration in physical and role functioning (p=0.012 and p=0.007, respectively). The symptom scales indicated a statistically significant improvement in appetite (p=0.003). The results of the QLQ-PR25 revealed that patients experienced an increase in hot flushes (p < 0.001) and erection problems and uncomfortable sexual intimacy among the sexual functioning items (p=0.030 and p=0.023, respectively), but day-time urinary frequency was improved (p=0.004). Conclusion. The results of this prospective study indicate that leuprolide acetate treatment was accompanied by improvements in global health status/QoL, despite a deterioration in physical, role and sexual function.

UR - http://www.scopus.com/inward/record.url?scp=78649268280&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649268280&partnerID=8YFLogxK

U2 - 10.3109/00365599.2010.508048

DO - 10.3109/00365599.2010.508048

M3 - Article

C2 - 20707648

AN - SCOPUS:78649268280

VL - 44

SP - 399

EP - 405

JO - Scandinavian Journal of Urology

JF - Scandinavian Journal of Urology

SN - 2168-1805

IS - 6

ER -